BioCryst Pharmaceuticals
(NASDAQ) BCRX
BioCryst Pharmaceuticals Financials at a Glance
Market Cap
$2.14B
Revenue (TTM)
$885.72M
Net Income (TTM)
-$457.98M
EPS (TTM)
-$1.78
P/E Ratio
-4.73
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Price
$8.33
Volume
34,918
Open
$8.46
Price
$8.33
Volume
34,918
Open
$8.46
Previous Close
$8.41
Daily Range
$8.25 - $8.46
52-Week Range
$6.00 - $11.23
Estimated Earnings Date
Aug 3, 2026
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Price
$8.33
Volume
34,918
Open
$8.46
Previous Close
$8.41
Daily Range
$8.25 - $8.46
52-Week Range
$6.00 - $11.23
Estimated Earnings Date
Aug 3, 2026
BCRX News
BCRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout BioCryst Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
435
CEO
Charles K. Gayer, MBA
Website
www.biocryst.comHeadquarters
Durham, NC 27703, US
BCRX Financials
Key Financial Metrics (TTM)
Gross Margin
19%
Operating Margin
-43%
Net Income Margin
-52%
Return on Equity
0%
Return on Capital
-1%
Return on Assets
-98%
Earnings Yield
-21.14%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.14B
Shares Outstanding
254.16M
Volume
34.92K
Avg. Volume
5.18M
Financials (TTM)
Gross Profit
$855.76M
Operating Income
$340.99M
EBITDA
$347.65M
Operating Cash Flow
$329.88M
Capital Expenditure
-$2.47M
Free Cash Flow
$327.41M
Cash & ST Invst.
$274.75M
Total Debt
$477.33M
BioCryst Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$156.41M
+7.5%
Gross Profit
-$546.73M
-487.8%
Gross Margin
-3.50%
N/A
Market Cap
$2.14B
N/A
Market Cap/Employee
$3.69M
N/A
Employees
580
N/A
Net Income
-$721.81M
-2255762.5%
EBITDA
-$701.60M
-2954.0%
Quarterly Fundamentals
Net Cash
-$618.83M
-15.9%
Accounts Receivable
$109.27M
+17.0%
Inventory
$5.99M
-12.9%
Long Term Debt
$814.67M
+2.8%
Short Term Debt
$43.41M
+16.8%
Return on Assets
-98.48%
N/A
Return on Invested Capital
-1.42%
N/A
Free Cash Flow
-$62.54M
-126.1%
Operating Cash Flow
-$62.14M
-125.8%